Announcements Trials
Browse Landscape

Phase

Phase 1 144Phase NA 62Phase 2 55Phase 1/2 39Phase EARLY_PHASE1 6Phase 3 6Phase 4 3Phase 2/3 3

Status

Completed 58Unknown 20Recruiting 16Active not recruiting 13Terminated 6Not yet recruiting 6Withdrawn 4Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 147Thoracic 125Genitourinary 96Breast 95Lymphoid 83Other hematologic neoplasm 76Gynecologic 51Head & Neck 41Dermatologic 33Myeloid 27Plasma cell 26CNS 25Sarcoma 23Classical hematology 23Other 13Endocrine 11Tumor-Agnostic 6NET 4Other solid neoplasm 3Other neoplasm 3

Conditions

Neoplasms 5Neoplasm Metastasis 2Carcinoma 1

Interventions

Trastuzumab 1Surveys and Questionnaires 1Mirtazapine 1Melatonin 1Lapatinib 1Fenretinide 1Everolimus 1Escitalopram 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Terminated × Tumor-Agnostic × Clear all
NCT03839940 2025-01-29

MIST

Alliance for Clinical Trials in Oncology

Phase 3 Terminated
39 enrolled 18 charts
Tumor-Agnostic

Neoplasms

NCT04763135 2023-06-08

MIR-P

Hospices Civils de Lyon

Phase 3 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02773966 2022-07-22

Kypho-IORT vs. EBRT in Spinal Metastases

Universitätsmedizin Mannheim

Phase 3 Terminated
6 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02454855 2022-06-13

MEQAPAG

Centre Jean Perrin

Phase 3 Terminated
123 enrolled
Tumor-Agnostic

Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

NCT01479192 2018-11-07

Fenretinide in Healthy Young Women at Genetic and Familial Risk

European Institute of Oncology

Phase 3 Terminated
20 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡